A Phase II Study of Abraxane, Carboplatin and Bevacizumab in "Triple Negative" (Demonstrating No Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Carboplatin; Paclitaxel
- Indications Advanced breast cancer
- Focus Adverse reactions
- 18 Feb 2015 Biomarkers information updated
- 10 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 31 Aug 2012 Planned end date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov.